Pandemic windfall spending picks up pace with CytomX investment

6 January 2023

One of the world’s leading specialists in mRNA therapeutics has partnered with California’s CytomX Therapeutics (Nasdaq: CTMX) to create novel cancer meds.

East Coast, USA-based Moderna (Nasdaq: MRNA) is best known for its role in tackling the coronavirus pandemic with the development of its Spikevax vaccine, helping save millions of lives while generating a windfall of tens of billions.

Matching that for its second approved product may be unrealistic, but the investment in CytomX and its Probody platform could be key in unlocking the potential of a new class of “conditionally activated” therapies in oncology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK